On 13-15 May 2024, the PRIME consortium reconvened for the 5th General Assembly (GA) meeting in the beautiful city of Bologna (Italy). PRIME, an EU-funded research project, aims to unravel the insulin-dependent mechanisms that underly both somatic conditions (i.e. type 2 diabetes, obesity, metabolic syndrome) and brain disorders (i.e. Alzheimer’s disease, obsessive-compulsive disorder, autism spectrum disorders). Until now, very little attention has been paid to the role of insulin signalling in brain disorders, and the overlap (or ‘multimorbidity’) with somatic conditions. Therefore, through PRIME, the aim is to develop tools for improved diagnosis, clinical care and prevention of insulin-related lifespan multimorbidity.
During the GA meeting, the latest research findings were discussed, and early career scientists were given opportunities to present their projects. The participants also enjoyed exploring the charms of Bologna. Additionally, an insightful keynote lecture was provided by Prof. Leszek Czupryniak on GLP-1 drugs, such as Ozempic. He elaborated on how these innovative drugs might enhance cognition and brain function in Alzheimer's disease, though further research is needed in this area. The consortium was also delighted to listen to talks from its project partners Alzheimer Europe, IDF Europe, and ADHD Europe about how to improve communication between researchers and individuals with lived experience. As always, communication is key!
PRIME is very grateful to have these initiatives on board and appreciates the constant exchange. It was wonderful for the members to reconnect and discuss the latest research results on insulin and brain disorders, in person. The time in Bologna was indeed inspiring and enriching. As the consortium enters the final seven months of the project, it is committed to diligently compiling collected data and connecting the dots. Angela Bradshaw represented Alzheimer Europe at the PRIME GA.
Read more about PRIME on the project website: https://prime-study.eu/
Follow PRIME on Social Media: X (former Twitter) and LinkedIn
